Trials / Unknown
UnknownNCT04755946
Possible Role of Roflumilast in Diabetic Nephropathy
Clinical Study Evaluating the Possible Efficacy and Safety of Roflumilast in Patients With Diabetic Nephropathy
- Status
- Unknown
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 48 (estimated)
- Sponsor
- Tanta University · Academic / Other
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
adding roflumilast to the standard therapy for diabetic nephropathy and studying the progression of many outcomes including urinary albumin to creatinine ratio, estimated GFR, biomarkers of diabetic nephropathy
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Roflumilast | adding one tablet of roflumilast 500 mcg to the standard ACEI (captopril) for diabetic nephropathy management |
| DRUG | Placebo | Placebo |
Timeline
- Start date
- 2021-03-10
- Primary completion
- 2021-06-10
- Completion
- 2021-07-10
- First posted
- 2021-02-16
- Last updated
- 2021-02-16
Source: ClinicalTrials.gov record NCT04755946. Inclusion in this directory is not an endorsement.